DK1278540T3 - Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose - Google Patents

Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose

Info

Publication number
DK1278540T3
DK1278540T3 DK01945064T DK01945064T DK1278540T3 DK 1278540 T3 DK1278540 T3 DK 1278540T3 DK 01945064 T DK01945064 T DK 01945064T DK 01945064 T DK01945064 T DK 01945064T DK 1278540 T3 DK1278540 T3 DK 1278540T3
Authority
DK
Denmark
Prior art keywords
atherosclerosis
inhibitors
prevention
treatment
Prior art date
Application number
DK01945064T
Other languages
Danish (da)
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Serono Lab
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab, Inst Nat Sante Rech Med filed Critical Serono Lab
Application granted granted Critical
Publication of DK1278540T3 publication Critical patent/DK1278540T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK01945064T 2000-05-05 2001-04-30 Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose DK1278540T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Publications (1)

Publication Number Publication Date
DK1278540T3 true DK1278540T3 (da) 2008-07-21

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01945064T DK1278540T3 (da) 2000-05-05 2001-04-30 Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose

Country Status (32)

Country Link
US (1) US20040076628A1 (sr)
EP (1) EP1278540B1 (sr)
JP (1) JP5122053B2 (sr)
KR (2) KR20030016254A (sr)
CN (2) CN1250286C (sr)
AR (1) AR035640A1 (sr)
AT (1) ATE395075T1 (sr)
AU (2) AU2001267390B2 (sr)
BG (1) BG65881B1 (sr)
BR (1) BRPI0110506B8 (sr)
CA (1) CA2407895C (sr)
CY (1) CY1110385T1 (sr)
CZ (1) CZ300792B6 (sr)
DE (1) DE60134009D1 (sr)
DK (1) DK1278540T3 (sr)
EA (2) EA005410B1 (sr)
EE (1) EE05056B1 (sr)
ES (1) ES2305082T3 (sr)
HR (1) HRP20020828A2 (sr)
HU (1) HU229375B1 (sr)
IL (2) IL152567A0 (sr)
ME (1) ME00554B (sr)
MX (1) MXPA02010895A (sr)
NO (1) NO329821B1 (sr)
PL (1) PL209371B1 (sr)
PT (1) PT1278540E (sr)
RS (1) RS50926B (sr)
SI (1) SI1278540T1 (sr)
SK (1) SK287761B6 (sr)
UA (2) UA78492C2 (sr)
WO (1) WO2001085201A2 (sr)
ZA (1) ZA200208228B (sr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
KR100857376B1 (ko) * 2001-01-29 2008-09-05 라보라토리스 세로노 에스.에이. 심장 질환의 치료 및/또는 예방에 사용되는 ｉｌ-18저해물질
HRP20030842B1 (hr) * 2001-05-25 2017-06-02 Ares Trading S.A. UPOTREBA IL-18 INHIBITORA ZA LIJEČENJE I PREVENCIJU OZLJEDA CNS-a
US6797727B2 (en) * 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
SI1487541T1 (sl) * 2002-03-22 2009-02-28 Serono Lab Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
ATE399872T1 (de) * 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
DK1622939T3 (da) 2003-05-13 2012-04-10 Merck Serono Sa Aktive varianter af det IL-18-bindende protein og medicinske anvendelser deraf
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP1755642B1 (en) * 2004-04-15 2010-01-13 Athera Biotechnologies Ab Annexin v for preventing plaque rupture
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
ES2385639T3 (es) 2005-06-03 2012-07-27 Ares Trading S.A. Producción de una proteína de unión a IL-18 recombinante
AU2006256763B2 (en) 2005-06-10 2012-08-02 Ares Trading S.A. Process for the purification of IL-18 binding protein
AR082518A1 (es) 2010-08-25 2012-12-12 Hoffmann La Roche Anticuerpos contra il-18r1 y usos de los mismos
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
PT3041864T (pt) 2013-09-05 2021-10-26 Ab2 Bio Sa Proteína de ligação a il-18 (il-18bp) em doenças inflamatórias
UA128752C2 (uk) 2015-03-05 2024-10-16 Аб2 Біо Са Фармацевтична композиція для лікування асоційованого з il-18 захворювання або порушення
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein

Also Published As

Publication number Publication date
CA2407895C (en) 2012-12-18
YU82602A (sh) 2006-01-16
CZ20023644A3 (cs) 2003-03-12
JP2003532685A (ja) 2003-11-05
IL152567A0 (en) 2003-05-29
BRPI0110506B8 (pt) 2021-05-25
NO329821B1 (no) 2010-12-27
WO2001085201A2 (en) 2001-11-15
AR035640A1 (es) 2004-06-23
SK15562002A3 (sk) 2003-05-02
CA2407895A1 (en) 2001-11-15
BRPI0110506B1 (pt) 2015-05-19
HK1055681A1 (en) 2004-01-21
CN1250286C (zh) 2006-04-12
US20040076628A1 (en) 2004-04-22
AU6739001A (en) 2001-11-20
NO20025307L (no) 2002-12-18
BG107218A (bg) 2003-06-30
HK1094909A1 (en) 2007-04-13
ATE395075T1 (de) 2008-05-15
UA87658C2 (uk) 2009-08-10
CZ300792B6 (cs) 2009-08-12
EE200200620A (et) 2004-06-15
EP1278540A2 (en) 2003-01-29
WO2001085201A3 (en) 2002-05-10
PL209371B1 (pl) 2011-08-31
EE05056B1 (et) 2008-08-15
PL365697A1 (en) 2005-01-10
EA200201175A1 (ru) 2003-04-24
ZA200208228B (en) 2005-07-27
SK287761B6 (en) 2011-09-05
SI1278540T1 (sl) 2008-10-31
CN1841066B (zh) 2012-08-29
HUP0301991A2 (hu) 2003-09-29
EA007014B1 (ru) 2006-06-30
KR20030016254A (ko) 2003-02-26
BR0110506A (pt) 2003-04-01
MEP64008A (en) 2011-12-20
CN1434722A (zh) 2003-08-06
CY1110385T1 (el) 2015-04-29
MXPA02010895A (es) 2003-03-27
ES2305082T3 (es) 2008-11-01
HRP20020828A2 (en) 2004-12-31
AU2001267390B2 (en) 2005-09-22
DE60134009D1 (de) 2008-06-26
PT1278540E (pt) 2008-07-03
EA005410B1 (ru) 2005-02-24
KR100798545B1 (ko) 2008-01-28
KR20070073989A (ko) 2007-07-10
CN1841066A (zh) 2006-10-04
JP5122053B2 (ja) 2013-01-16
IL152567A (en) 2010-12-30
HUP0301991A3 (en) 2006-11-28
NO20025307D0 (no) 2002-11-05
ME00554B (me) 2012-03-20
RS50926B (sr) 2010-08-31
EP1278540B1 (en) 2008-05-14
UA78492C2 (en) 2007-04-10
HU229375B1 (en) 2013-11-28
BG65881B1 (bg) 2010-04-30
EA200401183A1 (ru) 2004-12-30

Similar Documents

Publication Publication Date Title
NO20025307L (no) Anvendelse av IL-18 inhibitorer til behandling og/eller forebygging av aterosklerose
NO20032668D0 (no) Gyraseinhibitorer og anvendelser derav
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
IS6700A (is) Meðferðarblanda CETP hindra og atórvastatíns
NO20020343L (no) Kaspase-inhibitorer og anvendelse derav
NO20044195L (no) Biofosfoninsyrer for behandling og prevensjon av osteoprose
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
DK1427437T3 (da) Oxyntomodulin til forebyggelse eller behandling af overvægt
NO20000011D0 (no) Skumdempersammensetninger og fremgangsmåter
NO20015274D0 (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
DK1657310T3 (da) Fremgangsmåde til fremstilling af dihydroxyestere og derivater deraf
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20031806D0 (no) Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati
NO20042244L (no) Fenylsubstituerte triazoler og deres anvendelse som selektive inhibitorer av AKL5-kinease
IS7003A (is) Arómatisk súlfonhýdroxýamöt og notkun þeirra til tálmunar próteasa
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DK1337547T3 (da) Nuklease-baseret fremgangsmåde til detektion og kvantificering af oligonukleotider
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
PT1274700E (pt) Di-hidrobenzopiranos di-hidrobenzotiopiranos e tetra-hidroquinolinas para o tratamento de afeccoes mediadas por cox-2
DE60223540D1 (de) Mundschutz und mundschutzfolie
DK1456377T3 (da) Syn3-sammensætninger og fremgangsmåder
DK1079818T3 (da) Præparat omfattende IL-18 og topotecan til behandling og/eller forhindring af cancer
DK1381620T3 (da) Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer